On September 11th, innovative drug concept stocks have risen. As of the time of publication, $BEIGENE (06160.HK)$ rose 6.97%, reporting HKD 124.3; $KEYMED BIO-B (02162.HK)$ rose 4.92%, reporting HKD 37.35; $INNOCARE (09969.HK)$ rose 4.91%, reporting HKD 5.55; $WUXI APPTEC (02359.HK)$ Up 4.81%, at HKD 33.75. $REMEGEN (09995.HK)$ Up 4.63%, at HKD 12.66.
On the news front, the 2024 ESMO Congress will be held from September 13th to 17th, in Barcelona, Spain, both online and offline. Many innovative drug companies, including Hengrui, CSPC, Akeso, Innovent Bio, and Remegen, will collectively participate in the event.
Zhongtai Securities stated that looking ahead to September: market risk appetite is expected to recover, seize the turning point of Q3 fundamentals and industry catalysts. Looking ahead to the second half of the year, from a policy perspective: support for innovative drugs, equipment upgrades, the National Essential Drug List, etc. are expected to continue to advance; industry events: medical insurance negotiations, major conferences in the field of innovative drugs such as ESMO/WCLC/ASH/American Academy of Ophthalmology annual meeting, advancement of GLP-1 research, etc. are expected to generate catalysts.